NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
1.12
Dollar change
+0.04
Percentage change
3.70
%
IndexRUT P/E- EPS (ttm)-3.28 Insider Own72.19% Shs Outstand34.67M Perf Week-3.45%
Market Cap67.33M Forward P/E- EPS next Y-0.53 Insider Trans-0.07% Shs Float16.72M Perf Month-15.79%
Enterprise Value-40.82M PEG- EPS next Q-0.12 Inst Own21.92% Short Float4.31% Perf Quarter-9.68%
Income-198.87M P/S25.12 EPS this Y59.57% Inst Trans-39.98% Short Ratio3.39 Perf Half Y-82.50%
Sales2.68M P/B96.39 EPS next Y59.54% ROA-68.22% Short Interest0.72M Perf YTD-81.67%
Book/sh0.01 P/C0.44 EPS next 5Y45.66% ROE-245.59% 52W High22.50 -95.02% Perf Year-83.26%
Cash/sh2.53 P/FCF- EPS past 3/5Y13.12% 7.57% ROIC-528.32% 52W Low0.92 21.74% Perf 3Y-94.04%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin-243.45% Volatility8.48% 6.78% Perf 5Y-98.45%
Dividend TTM- EV/Sales-15.23 EPS Y/Y TTM23.82% Oper. Margin-6398.81% ATR (14)0.09 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.71 Sales Y/Y TTM27.36% Profit Margin-7417.79% RSI (14)41.12 Recom4.00
Dividend Gr. 3/5Y- - Current Ratio5.71 EPS Q/Q-4.36% SMA20-8.12% Beta0.48 Target Price0.88
Payout- Debt/Eq62.80 Sales Q/Q0.40% SMA50-9.61% Rel Volume1.14 Prev Close1.08
Employees149 LT Debt/Eq52.77 EarningsMay 08 SMA200-80.78% Avg Volume212.80K Price1.12
IPOSep 18, 2019 Option/ShortYes / Yes EPS/Sales Surpr.-148.05% -88.24% Trades Volume241,504 Change3.70%
Date Action Analyst Rating Change Price Target Change
Jan-10-25Downgrade Stifel Buy → Hold $27 → $2.50
Jan-10-25Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $1.50
Jan-10-25Downgrade Morgan Stanley Equal-Weight → Underweight $12 → $2
Jan-10-25Downgrade Guggenheim Buy → Neutral
Jan-10-25Downgrade BMO Capital Markets Outperform → Market Perform $21 → $2
Dec-06-24Initiated BMO Capital Markets Outperform $21
Oct-01-24Downgrade Truist Buy → Hold $24 → $12
Oct-01-24Downgrade JP Morgan Neutral → Underweight $12 → $9
Feb-09-24Upgrade RBC Capital Mkts Sector Perform → Outperform $9 → $21
Dec-15-23Downgrade BofA Securities Buy → Neutral $8
Jun-12-25 09:20AM
May-13-25 05:45PM
May-12-25 05:40PM
May-08-25 08:25AM
Feb-27-25 10:00AM
09:35AM Loading…
Feb-05-25 09:35AM
Jan-11-25 10:55AM
Jan-10-25 12:43PM
07:55AM
06:43AM
Jan-09-25 01:00PM
10:00AM
Nov-08-24 08:00AM
07:00AM
Nov-04-24 07:00AM
05:09PM Loading…
Oct-01-24 05:09PM
04:03PM
02:39PM
11:40AM
09:52AM
08:00AM
Sep-30-24 04:01PM
Sep-18-24 09:33AM
Sep-10-24 04:05PM
Aug-22-24 12:00PM
Aug-14-24 08:00AM
07:00AM
Jul-12-24 09:35AM
May-29-24 07:00AM
May-10-24 02:38PM
07:38AM Loading…
May-09-24 07:38AM
May-08-24 10:55PM
05:55PM
04:10PM
May-07-24 07:00AM
May-03-24 10:00AM
Apr-30-24 12:00PM
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
04:10PM
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weber StevenPRINCIPAL ACCOUNTING OFFICERJun 16 '25Sale1.2048658326,530Jun 20 08:24 PM
Tahir MisbahCHIEF FINANCIAL OFFICERJun 16 '25Sale1.201,5221,825178,802Jun 20 08:23 PM
Harler Mary BethChief Executive OfficerJun 16 '25Sale1.201,5221,825338,181Jun 20 08:20 PM
Decker Lisa LynnCHIEF BUSINESS OFFICERJun 16 '25Sale1.209511,14072,578Jun 20 08:19 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERMay 14 '25Sale1.121,8652,09027,016May 16 04:05 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERMar 14 '25Sale1.231,7012,09228,881Mar 18 07:10 PM
Tahir MisbahCHIEF FINANCIAL OFFICERMar 14 '25Sale1.237,3299,015180,324Mar 18 07:09 PM
Harler Mary BethChief Executive OfficerMar 14 '25Sale1.237,3299,015339,703Mar 18 07:08 PM
Decker Lisa LynnCHIEF BUSINESS OFFICERMar 14 '25Sale1.234,5125,55073,529Mar 18 07:07 PM
Misbah TahirOfficerMar 14 '25Proposed Sale1.298,25910,654Mar 14 07:17 PM
Mary Beth HarlerOfficerMar 14 '25Proposed Sale1.298,25910,654Mar 14 07:16 PM
Lisa Lynn DeckerOfficerMar 14 '25Proposed Sale1.295,0796,552Mar 14 07:14 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERJan 15 '25Sale1.701,1221,90730,582Jan 17 05:54 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERDec 16 '24Sale7.485394,03231,704Dec 18 07:12 PM
Decker Lisa LynnCHIEF BUSINESS OFFICERDec 16 '24Sale7.481,0637,95178,041Dec 18 07:11 PM
Harler Mary BethChief Executive OfficerDec 16 '24Sale7.481,70812,776347,032Dec 18 07:11 PM
Tahir MisbahCHIEF FINANCIAL OFFICERDec 16 '24Sale7.481,70812,776187,653Dec 18 07:10 PM
Fred SchwarzerFormer Officer and DirectorDec 16 '24Proposed Sale7.1732,250231,232Dec 16 05:36 PM
Bruce KeytFormer OfficerDec 16 '24Proposed Sale7.1718,762134,524Dec 16 05:34 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERSep 13 '24Sale11.544695,41225,543Sep 17 08:58 PM
Takimoto Chris HCHIEF MEDICAL OFFICERSep 13 '24Sale11.541,48717,158154,331Sep 17 08:55 PM
Tahir MisbahCHIEF FINANCIAL OFFICERSep 13 '24Sale11.541,48717,158122,694Sep 17 08:54 PM
Schwarzer FredCEO AND PRESIDENTSep 13 '24Sale11.543,94645,532250,124Sep 17 08:52 PM
Keyt BruceCHIEF SCIENTIFIC OFFICERSep 13 '24Sale11.541,48717,158242,948Sep 17 08:50 PM
Harler Mary BethHead, Research & AutoimmunitySep 13 '24Sale11.541,48717,158163,740Sep 17 08:44 PM
Decker Lisa LynnCHIEF BUSINESS OFFICERSep 13 '24Sale11.5492510,67379,104Sep 17 08:42 PM
Hambleton JulieDirectorJul 25 '24Option Exercise1.3915,13221,03317,132Jul 29 05:45 PM
Hambleton JulieDirectorJul 25 '24Sale14.0015,132211,8482,000Jul 29 05:45 PM